The case for & against
Bull & Bear analysis
Bullish
Evolent Health (NYSE: EVH) operates within the healthcare services sector, specializing in innovative solutions for managing medical expenses, particularly in oncology and specialty technologies. The company employs performance-based revenue models alongside advanced AI capabilities to streamline processes for healthcare providers. Positioned in a critical niche, Evolent emphasizes enhancing patient outcomes while navigating challenges posed by evolving regulatory environments and competitive market dynamics.
Bull says
- ↑Q2 revenue $653M soared 31% QoQ; full-year guide upped to $2.6–2.7B
- ↑Oncology performance suite deal set to add ~$300M annual revenue
- ↑AI-driven auto-approval rates jumped from 55% to 75%, boosting efficiency
- ↑Adjusted EBITDA $28M (+27% QoQ); performance suite rev $485M up 50% QoQ
- ↑80% of analysts rate Buy; strong book-to-price ratio suggests undervaluation
- ↑Manageable leverage with net debt $808M and stable debt ratios
Bear says
- ↓MER stood at a high 95% in Q2 and may rise further in Q3
- ↓Medicaid expansion membership projected to decline 20%, cutting revenue ~4–5%
- ↓Net debt of $808M strains financial flexibility and raises interest burdens
- ↓Profitability metrics remain weak, undermining return potential
- ↓Oncology market overcrowded; low share limits growth prospects
- ↓High volatility risk and smaller size may drive unpredictable stock swings
Investment themes with EVH
Health Care Providers↓ -0.37%
UNH · CVS · HCA
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 05-10-2025bullish
Transcript signals
Bull points
- Evolent had a strong first quarter with above-expectations revenue growth and adjusted EBITDA in line with the first quarter guidance.
- We are pleased with our first quarter results and anticipate the continued solid outlook for 2024.
- We are raising the midpoint of our revenue guidance by $115 million and reiterating both our in-year adjusted EBITDA outlook of $235 million to $265 million and our 2024 year-end exit run rate of $300 million in adjusted EBITDA.
Read full transcript analysis ›